Abstract:Feng Gao, 1, 2, * Ming Li, 1, 3, 4, * Wenbin Liu, 5 Wei Li 2, 6 1 Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China; 2 Department of Ultrasonography, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, People's Republic of China; 3 School of Stomatology, Hunan University of Chinese Medicine, Changsha, Hunan 410208, People's Republic of China; 4 Changsha Stomatological Hospital, Hunan University of Chinese Medicine, Changsha, Hunan, 410004, People's Republic of China; 5 Department of Pathology, The Affiliated Hunan Cancer Hospital of Central South University, Changsha, Hunan 410013, People's Republic of China; 6 Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, People's Republic of China *These authors contributed equally to this work Correspondence: Wei Li Tel +86 731-88618643 Email weililx@csu.edu.cn Background: Deregulation of epidermal growth factor receptor (EGFR) signaling plays a critical role in non-small cell lung cancer (NSCLC) tumorigenesis. The natural product Tanshinone IIA (Tan IIA) exhibits significant anti-tumor effect in various human cancers, however, the mechanism remains elusive. Methods: The inhibitory effect of Tan IIA NSCLC cells was determined by MTS and soft agar assays. The activation of EGFR signaling and the protein level of myeloid cell leukemia 1 (Mcl-1) were examined by immunoblot (IB), immunohistochemical staining (IHC), and ubiquitination analysis. The in vivo anti-tumor effect was validated by the xenograft mouse model. Results: Tan IIA inhibits NSCLC cells through suppression of EGFR signaling. Tan IIA decreases cell viability and colony formation in EGFR wild type and activating mutant cell lines. The IB data further confirmed that Tan IIA suppresses EGFR phosphorylation time- and dose-dependently. Tan IIA destabilizes Mcl-1 and shortens the half-life. Ubiquitination analysis showed that treatment with Tan IIA promotes Mcl-1 ubiquitination and degradation. Further study showed that the downregulation of EGFR-Akt signaling is required for Tan IIA-induced Mcl-1 reduction. Ectopic overexpression of constitutively activated Akt1 compromised these antitumor efficacies in Tan IIA-treated NSCLC cells. Finally, Tan IIA inhibited the in vivo tumor growth. Conclusion: Our data indicate that Tan IIA acts as an EGFR signaling inhibitor, and targeting EGFR-Akt-Mcl1 axis could provide a new option for NSCLC treatment. Keywords: non-small cell lung cancer, Tanshinone IIA, epidermal growth factor receptor, Mcl-1, ubiquitination

D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC

Arsenic Circumvents the Gefitinib Resistance by Binding to P62 and Mediating Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer

D-mannose Targets PD-1 to Lysosomal Degradation and Enhances T Cell-Mediated Anti-Tumor Immunity

D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1

Mannose Impairs Lung Adenocarcinoma Growth and Enhances the Sensitivity of A549 Cells to Carboplatin.

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy.

D-mannose promotes the degradation of IDH2 through upregulation of RNF185 and suppresses breast cancer

Inhibitory effect of 1,4,5,6-tetrahydroxy-7,8-diprenylxanthone against NSCLC with L858R/T790M/C797S mutant EGFR

Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway

EGFR-AS1 Promotes Nonsmall Cell Lung Cancer (NSCLC) Progression via Downregulating the miR-524-5p/DRAM1 Axis and Inhibiting Autophagic Lysosomal Degradation

Ursolic Acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in NSCLCs harboring EGFR T790M.

Marsdenia Tenacissima Extract Overcomes Axl- and Met-mediated Erlotinib and Gefitinib Cross-Resistance in Non-Small Cell Lung Cancer Cells

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

DRAM1 Plays a Tumor Suppressor Role in NSCLC Cells by Promoting Lysosomal Degradation of EGFR

DNMT3A governs tyrosine kinase inhibitors responses through IAPs and in a cell senescence-dependent manner in non-small cell lung cancer

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.

Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer

Marsdenia Tenacissima Extract Enhances Gefitinib Efficacy in Non-Small-Cell Lung Cancer Xenografts

Inhibition of EGFR Signaling and Activation of Mitochondrial Apoptosis Contribute to Tanshinone IIA-Mediated Tumor Suppression in Non-Small Cell Lung Cancer Cells